Oxidative Stress & Detoxification Support

A three-amino-acid peptide every cell makes to neutralize oxidative damage; supplements may raise blood levels modestly, but proof of health benefits in people is limited.

Overview

Glutathione is a tripeptide built from glutamate, cysteine and glycine, made inside nearly every cell. It is the body's most abundant small antioxidant, used to defuse hydrogen peroxide and to tag toxins for removal^[1]. The body makes its own supply, and cysteine availability is often the limiting ingredient, which is why precursors such as N-acetylcysteine are also studied^[1]. Supplemental glutathione is sold in oral, liposomal and injectable forms.

The central question is whether glutathione taken from outside reaches the places it works. A four-week oral trial found no change in blood glutathione or oxidative damage markers^[3], while a six-month trial found modest increases in blood glutathione stores^[2]. A small IV trial in Parkinson's disease found no significant benefit^[4]. Human evidence is real but small, short and inconsistent.

Mechanism of Action

Cells build glutathione in two steps: glutamate cysteine ligase joins glutamate and cysteine, then glutathione synthase adds glycine^[1]. The reduced form (GSH) donates electrons through glutathione peroxidase to convert hydrogen peroxide into water, becoming oxidized glutathione (GSSG) in the process. Glutathione reductase, which needs riboflavin-derived cofactors, then recycles GSSG back to GSH. The GSSG to GSH ratio is widely used as a marker of oxidative stress^[1]. Separately, glutathione S-transferase enzymes attach glutathione to drugs and environmental chemicals so they can be excreted^[1].

Getting supplemental glutathione into cells is the weak link. As a peptide it can be broken down by digestive enzymes, and studies of oral forms disagree on whether blood levels rise^[1,3]. In the six-month trial, levels did rise in red cells, plasma and immune cells, then returned to baseline within a month of stopping^[2]. Liposomal, sublingual and intravenous forms are proposed to bypass digestion, but the studies behind them are small, and the best delivery route remains unresolved^[1]. Raising blood levels does not by itself show that tissue glutathione or health outcomes change.

What the Research Shows

• Oral glutathione RCT, Eur J Nutr 2015 (n=54 healthy non-smoking adults, 6 months, two strengths vs placebo): the higher strength raised glutathione 30 to 35% in red cells, plasma and lymphocytes and 260% in cheek cells (P<0.05); natural killer cell activity more than doubled at 3 months. Levels returned to baseline after a 1-month washout^[2].
• Oral glutathione RCT, J Altern Complement Med 2011 (n=40 healthy adults, 4 weeks): no change in urinary oxidative damage markers (F2-isoprostanes P=0.38, 8-OHdG P=0.27) or in red-cell glutathione^[3].
• IV glutathione pilot RCT in Parkinson's disease, Mov Disord 2009 (n=21, 4 weeks): motor and daily-living scores improved 2.8 points more than placebo, which was not significant (P=0.32), and the difference reversed after stopping^[4].
• Open-label pilot in fatty liver disease, BMC Gastroenterol 2017 (n=34 enrolled, 29 completed, 4 months oral): liver enzyme ALT fell significantly, but there was no control group^[5].
• Liposomal form, small study (n=12, 4 weeks): changes were mostly not significant, with one transient plasma rise of about 25%^[1].

• Animal and laboratory research on glutathione mostly manipulates the body's own production rather than testing supplements, so it is not summarized here; the human trials above are more directly relevant^[1].

Open Questions

• Whether oral glutathione is absorbed intact or mainly broken down and rebuilt from its amino acids is still debated^[1].
• Whether raising blood glutathione changes tissue levels or any clinical outcome is untested in adequately sized trials^[2,3].
• Which form (oral, liposomal, sublingual, IV) works best has not been compared head to head^[1].
• The positive trials are small and single-center, and no large replication exists^[2,4,5].

Regulatory Status

Glutathione is not an FDA-approved drug for any indication. As of May 2026, glutathione for compounding sits in FDA's 503A Category 1 (bulk substances under evaluation), so pharmacies may compound it while review continues^[6].

Related Compounds

A tiny four-amino-acid peptide that parks on the inner membrane of mitochondria, now FDA-approved (on an accelerated basis) for one rare inherited mitochondrial disease, Barth syndrome.

Overview

SS-31, developed as elamipretide (earlier code names MTP-131 and Bendavia), is a synthetic tetrapeptide designed to slip into cells and concentrate on the inner membrane of mitochondria, where it binds a fat molecule called cardiolipin^[2,7]. In September 2025 the FDA granted it accelerated approval as Forzinity, the first treatment for Barth syndrome, a rare genetic disorder in which cardiolipin is built incorrectly^[1].

That approval is narrow and conditional. It rests on knee muscle strength measured in an uncontrolled extension of a 12-person trial, after the randomized phase missed its main goals^[2]. Larger trials in other conditions, including a 218-person mitochondrial myopathy trial and a heart attack trial, did not meet their primary endpoints^[5,6]. The approval does not extend to aging or general energy claims.

Mechanism of Action

Elamipretide alternates positive charges with aromatic rings (D-Arg-2,6-dimethyl-Tyr-Lys-Phe-NH₂), a pattern that lets it cross cell membranes and accumulate on the inner mitochondrial membrane^[2]. There it binds cardiolipin, a phospholipid found almost only in that membrane, which anchors the electron transport chain and shapes the folded cristae. In isolated mitochondria and rat ischemia models, SS-31 binding to cardiolipin protected cytochrome c from turning into a damaging peroxidase, preserved cristae structure and helped restore ATP production after blood flow returned^[7].

Barth syndrome is caused by mutations in the TAZ gene, which leave cardiolipin with the wrong fatty acid chains and raise the ratio of monolysocardiolipin to cardiolipin. In the long-term TAZPOWER extension, that ratio fell significantly with treatment, a biomarker change consistent with the proposed mechanism^[4]. The label describes elamipretide simply as a mitochondrial cardiolipin binder and does not claim it repairs the underlying genetic defect^[2]. After injection under the skin it is about 92% bioavailable, broken into inactive fragments and cleared by the kidneys^[2].

What the Research Shows

• TAZPOWER crossover RCT plus extension, per FDA label (n=12 with Barth syndrome, 12 weeks per arm, then open-label): elamipretide was not superior to placebo on the 6-minute walk test or fatigue score, and knee strength did not improve in the randomized phase (median +4 vs -5 newtons). In the uncontrolled extension, median knee extensor strength rose 34 to 68 newtons from a baseline of 124, with 8 people still assessed at week 168^[2].
• TAZPOWER 168-week extension, Genet Med 2024 (n=8 at week 168): walking distance improved from baseline, some heart volume measures improved, and the cardiolipin biomarker ratio fell. Ejection fraction did not change significantly. There was no control group^[4].
• MMPOWER-3 phase 3 RCT, Neurology 2023 (n=218 adults with primary mitochondrial myopathy, 24 weeks): no benefit on the 6-minute walk test (difference -3.2 m, P=0.69) or fatigue (P=0.37). A subgroup with nuclear DNA mutations walked 25.2 m farther than placebo (P=0.03), which the authors called hypothesis generating^[5].
• EMBRACE STEMI phase 2a RCT, Eur Heart J 2016 (n=297 randomized, 118 in primary analysis, IV during heart attack treatment): infarct size by CK-MB was not reduced (5,570 vs 5,785 ng·h/mL, not significant), and MRI and clinical outcomes did not differ^[6].

• Rats, kidney ischemia-reperfusion: SS-31 preserved mitochondrial cristae, protected cardiolipin-bound cytochrome c and sped ATP recovery after blood flow was restored^[7].
• Aged mice (27 months), skeletal muscle: a single injection restored muscle mitochondrial energetics toward young levels within an hour, and 8 days of treatment increased whole-animal endurance^[8].

• Isolated mitochondria and cardiolipin membranes: SS-31 bound cardiolipin and inhibited cytochrome c peroxidase activity, the step that oxidizes cardiolipin during injury^[7].

Open Questions

• Whether stronger knee muscles translate into real-world benefit (walking, daily function, survival) in Barth syndrome is exactly what the confirmatory trial must show^[1,3].
• The approval rests on 8 to 10 people in an open-label extension with no control group, so placebo effects and natural variation cannot be excluded^[2].
• Benefit in other mitochondrial diseases is unproven; a nuclear-DNA subgroup signal and a dry macular degeneration phase 3 trial (readout expected late 2027) are still being tested^[5,9].
• There is no human evidence that it slows aging or improves energy in healthy people.

Regulatory Status

FDA accelerated approval (NDA 215244, Forzinity) on September 19, 2025, for Barth syndrome patients weighing at least 30 kg; continued approval depends on a randomized confirmatory trial, which began dosing in 2026^[1,3]. It is not approved by the EMA, and all other uses, including aging, remain investigational^[3,9].

Related Compounds